Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On October 17, 2025, Telomir Pharmaceuticals entered into a binding Letter of Intent with TELI Pharmaceuticals to acquire all outstanding shares of TELI through a stock-for-stock exchange. This transaction aims to consolidate worldwide intellectual property and development rights for Telomir-1, positioning Telomir for global market expansion and value growth. The agreement includes a $5 million cash contribution from certain TELI shareholders to support the transaction and future development activities. This strategic move is expected to simplify global development and partnership efforts, aligning U.S. and ex-U.S. rights to Telomir-1 within a single public company structure.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of oral epigenetic therapies for cancer, aging, and age-related diseases. The company’s primary product in development is Telomir-1, which is currently in preclinical stages.
Average Trading Volume: 3,012,134
Technical Sentiment Signal: Sell
Current Market Cap: $50.68M
For an in-depth examination of TELO stock, go to TipRanks’ Overview page.